Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.05 USD | +4.31% | +3.69% | -33.06% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 63% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-33.06% | 579M | B- | ||
+75.69% | 12.57B | B- | ||
-24.68% | 7.34B | C+ | ||
+6.22% | 6.61B | C- | ||
+12.58% | 5.39B | D+ | ||
+26.90% | 4.53B | - | ||
-21.14% | 3.91B | B- | ||
-22.99% | 2.91B | C | ||
+47.42% | 2.37B | C- | ||
-0.37% | 2B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SIBN Stock
- Ratings SI-BONE, Inc.